Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Capecitabine for 5-Fluorouracil-Resistant Brain Metastases From Breast Cancer

Wang, Michael L. H. M.D.; Yung, W. K. Alfred M.D.; Royce, Melanie E. M.D.; Schomer, Donald F. M.D.; Theriault, Richard L. D.O., M.B.A.

American Journal of Clinical Oncology: August 2001 - Volume 24 - Issue 4 - p 421–424

We report a case in which brain metastases originating from breast cancer responded to treatment with oral capecitabine. The metastases had progressed and Karnofsky performance status deteriorated despite whole brain irradiation, hormonal treatment, and systemic chemotherapy that included 5-fluorouracil (5-FU). In contrast, 2 months of treatment with oral capecitabine produced a partial response, documented by lesion size on magnetic resonance imaging and an improvement in performance status; both measures continued to improve during 11 months of capecitabine treatment.

From the Division of Cancer Medicine (M.L.H.W.) and the Departments of Breast Medical Oncology (M.E.R., R.L.T.), Neuro-Oncology (W.K.A.Y.), and Diagnostic Radiology (D.F.S.), The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

Address correspondence and reprint requests to Christine F. Wogan, Department of Scientific Publications, Box 234, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, U.S.A.

© 2001 Lippincott Williams & Wilkins, Inc.